Puma Biotechnology, Inc.
NASDAQ: PBYI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alan H. Auerbach
- Employees
- 172
- Headquarters
- Los Angeles, United States
- IPO year
- 2012
- Market cap
- $404.7M
- Website
- https://www.pumabiotechnology.com
Loading PBYI…
Loading profile data…Frequently asked questions about PBYI
What does Puma Biotechnology, Inc. (PBYI) do?
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well...
Where does PBYI trade?
Puma Biotechnology, Inc. (PBYI) trades on the NASDAQ Global Select.
What sector is PBYI in?
Puma Biotechnology, Inc. (PBYI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Puma Biotechnology, Inc.?
Alan H. Auerbach is the chief executive officer of Puma Biotechnology, Inc. (PBYI).
Where is Puma Biotechnology, Inc. headquartered?
Puma Biotechnology, Inc. is headquartered in United States.
Does PBYI pay a dividend?
Puma Biotechnology, Inc. (PBYI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PBYI go public?
Puma Biotechnology, Inc. (PBYI) completed its initial public offering in 2012.